News Column

Trevena to Present at the 16th Annual BIO CEO & Investor Conference

February 19, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company and a leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. ET in New York City (see also Trevena, Inc.).

To access a live audio webcast of the presentation, please visit the "Investors" section at www.trevenainc.com. The webcast will be archived for 90 days. About Trevena Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. In addition to TRV734, Trevena has applied its proprietary product platform to identify and advance two other differentiated product candidates into the clinic -- TRV027 to treat acute heart failure, and TRV130 to treat moderate to severe acute pain intravenously. Trevena also plans to advance additional preclinical product candidates.

Keywords for this news article include: Trevena Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools